Portfolio Lab

Sanofi

  • Stock
  • Ticker SNY
  • ISIN US80105N1054
  • Nasdaq
  • US listing in dollars (ADR)

Health care · Pharmaceuticals · France

$46.52 +1.00%
Close of 20 Nov 2026
Open in backtest

Performance, volatility and drawdowns of Sanofi since 11/2016, with distributions reinvested and calculated in US dollars. As of 20 Nov 2026.

Performance

SNYGlobal equities (VT)

$10,000 grew to $17,479. Global equities (VT): $29,042.

Distributions reinvested, before taxes and brokerage costs. Dashed: Global equities (VT) for comparison.

Declines from the peak

Lowest point −33.5% in 09/2022, measured from the peak in 05/2022. It took 11 months to get back to the old peak.

1-year return
+0.5%
5-year return p.a.
+2.6%
10-year return p.a.
+5.7%
Volatility p.a.
19.3%
Largest decline
−33.5%

Financial statements

Amounts in € millions from the company's annual financial reports, earnings per share in € per ordinary share

Fiscal year202020212022202320242025
Income statement
Gross profit25,21226,92031,69432,20831,08133,667
Operating income14,1418,12610,6567,8757,2526,344
Net income12,3506,2798,4845,4365,6187,851
Earnings per share9.774.956.664.304.436.37
Balance sheet
Total assets114,529120,242126,722126,464132,798126,805
Liabilities51,38251,21151,57052,11154,94155,095
Equity63,14769,03175,15274,35377,85771,710
Cash13,91510,09812,7368,7107,4417,657
Long-term debt19,74517,12314,85714,34711,79114,248
Cash flow
Operating cash flow7,44910,52210,52610,2589,08110,750
Capital expenditure-2,114-2,043-2,201-3,024-3,195-3,538
Free cash flow5,3358,4798,3257,2345,8867,212

Annual returns

Best year 2019 at +20.5%, weakest 2020 at +0.4%. 9 of 9 full years were positive. * partial year.

Key metrics

Key figures as of 21 Nov 2026 from the company's latest annual financial report, amounts converted to US dollars at the ECB reference rate. Valuation and market cap appear only where price and earnings per share reliably refer to the same share.

Valuation

Market cap
€103bn
Market cap in trading currency
$114bn
Enterprise value
$126bn
P/E
13.3
P/S
–
P/B
1.45
EV/Sales
–
EV/EBITDA
–
Earnings yield
7.5%
FCF yield
7.0%

Results (latest fiscal year)

Revenue
–
Gross profit
$37.0bn
EBITDA
–
Net income
$8.59bn
Earnings per share
$7.00
Revenue growth
–
Earnings growth
+40.5%

Profitability

Gross margin
–
Operating margin
–
Net margin
–
Return on equity
10.5%
Return on assets
6.2%

Balance sheet and cash flow

Cash
$8.42bn
Financial debt
$20.4bn
Debt/equity %
26
Current ratio
1.09
Book value per share
$64.26
Operating cash flow
$11.8bn
Free cash flow
$7.93bn

Dividend

Dividend yield
5.21%
Dividend (12 months)
$2.42
Yield (12 months)
5.21%
Payout ratio
61%
Ex-dividend date
4 May 2026

Shares and trading

Shares outstanding
1.22bn
Volume
4.28m
Avg. volume 3 months
3.43m
Relative volume
1.3

Price and technicals

Price
$46.52
1 day
+1.0%
52-week high
$50.28
52-week low
$39.12
Distance to 52-week high
−7.5%
Distance to 52-week low
+18.9%
Distance to 50-day line
+8.0%
Distance to 200-day line
+4.9%
RSI (14)
57
Volatility 1M
26.2%

Performance

1 week
−3.8%
1 month
+10.9%
3 months
+1.8%
6 months
+5.0%
YTD
−4.0%
1 year
−6.1%

Dates

Fiscal year end
31 Dec 2025

Frequently asked questions

How has SNY performed since 11/2016?

$10,000 grew to $17,479 by 20 Nov 2026, which is +5.7% per year. Distributions are reinvested; taxes and brokerage costs are not deducted.

How volatile is SNY?

Volatility was 19.3% per year, measured on monthly returns. The largest decline from a peak was −33.5%, with the low in 09/2022.

How does SNY compare with a broad equity ETF?

Over the same period Global equities (VT) returned +11.3% per year at 15.1% volatility, SNY returned +5.7% at 19.3%. The correlation of monthly returns was 0.38; 1 would mean they moved in lockstep.

Which currency are the figures in?

In US dollars, the currency of the US listing.

Why does this page show a US listing?

The figures use the stock's depositary receipt (ADR) traded in the US. On individual days its path differs slightly from the price on the home exchange.

Not investment advice. Key figures and financial statements calculated from the company's annual financial reports, without guarantee; key figures converted to US dollars at the ECB reference rate, statements in the currency of the report.

Reference data of securities: source ESMA (FIRDS reference data) and SEC (EDGAR).

Not investment advice: results in Portfolio Lab are model calculations based on historical data and your inputs. Past performance is not a reliable indicator of future results.

Sanofi (SNY): Return and risk | Portfolio Lab